Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI -0.54%70 Days Inventory is 187.85 as of Mar. 2026, which is 6% above its 10-year median of 176.94. GuruFocus rates NSE:BALAXI with a GF Score™ of 70/100 and a GF Value™ of ₹69.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks worse than 61.54% on this metric.
The historical rank and industry rank for Balaxi Pharmaceuticals's Days Inventory or its related term are showing as below:
NSE:BALAXI'
s Days Inventory Range Over the Past 10 Years
Min: 9.25 Med: 176.94 Max: 265.48
Current: 193.61
During the past 12 years, Balaxi Pharmaceuticals's highest Days Inventory was 265.48. The lowest was 9.25. And the median was 176.94.
NSE:BALAXI's Days Inventory is ranked worse than 61.54% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs NSE:BALAXI: 193.61
Inventory Turnover measures how fast the company turns over its inventory within a year.
Balaxi Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.49.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Balaxi Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.18.
Balaxi Pharmaceuticals (NSE:BALAXI) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Balaxi Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Balaxi Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Balaxi Pharmaceuticals Days Inventory Related Terms
Balaxi Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Balaxi Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BALAXI vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Balaxi Pharmaceuticals (NSE:BALAXI) has a Days Inventory of 187.85 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Balaxi Pharmaceuticals and its competitors. This is near median its historical median of 176.94. Over the past decade, Balaxi Pharmaceuticals' Days Inventory has ranged from 9.25 to 265.48. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #568 out of 923 companies in the Drug Manufacturers industry, placing it in the top 61.5%.
Is Balaxi Pharmaceuticals' Days Inventory too high?
Balaxi Pharmaceuticals' current Days Inventory of 187.85 is near median its 10-year median of 176.94. Over the past 10 years, this metric has ranged from a low of 9.25 to a high of 265.48. The Drug Manufacturers industry median Days Inventory is 164.48. Balaxi Pharmaceuticals' value of 187.85 is 14.2% above this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #568 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Balaxi Pharmaceuticals has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #568 out of 923 companies for Days Inventory. This places Balaxi Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 164.48. Balaxi Pharmaceuticals' value of 187.85 is 14.2% above this benchmark. Historically, Balaxi Pharmaceuticals' own Days Inventory has ranged from 9.25 to 265.48 over the past decade. While the company's 10-year median is 176.94 vs. the industry median of 164.48, Balaxi Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current Days Inventory of 187.85 is 14.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current Days Inventory is 187.85, which is near median its own 10-year median of 176.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.51, compared to a current price of ₹24.04 — trading 65.4% below its estimated fair value. The current Days Inventory is 187.85, which is near median its 10-year median of 176.94 and 14.2% above the Drug Manufacturers industry median of 164.48. Balaxi Pharmaceuticals' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Days Inventory is 187.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.04 is trading 65.4% below its estimated GF Value™ of ₹69.51.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
Days Inventory: 187.85 (near median its 10-year median of 176.94)
GF Value™: ₹69.51 vs. price of ₹24.04 (65.4% below fair value)
Industry Position: 14.2% above the Drug Manufacturers median (#568 of 923)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
70GF Score
Get the complete analysis for NSE:BALAXI
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
